CoChat
Sign Up
Cited by 164

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting

Huynh, Ngoc Trinh, Roger, Emilie, Lautram, Nolwenn, Benoît, Jean-Pierre, Passirani, Catherine·2010·Nanomedicine
DOI 10.2217/nnm.10.113
Open this paper in CoChat — free account

Abstract

Research in designing and engineering long-circulating nanoparticles, so-called 'stealth' nanoparticles, has been attracting increasing interest as a new platform for targeted drug delivery, especially in chemotherapy. In particular, the modification of nanoparticulate surfaces with poly(ethylene glycol) derivatives has illustrated a decreased uptake of nanoparticles by mononuclear phagocyte system cells and, hence, an increased circulation time, allowing passive accumulation in the tumor. The clinical trials on patients with solid tumors are described in this article, to illustrate this generation of promising nanoparticles. In the last few years, the new-generation technique of grafting ligands on the nanoparticle surface in order to target and penetrate specific cancer cells has been developed. This article discusses the benefits of passive targeting for drug delivery to the solid tumors via the enhanced permeability and retention effect, when using stealth nanoparticles, and compares them with the advantages of active targeting.

Overview

Integrity signals

Registry

Crossref · 10.2217/nnm.10.113

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Research works printed but not linked: 198

  1. 10.1016/j.yexmp.2008.12.004 · DOI
  2. Moghimi SM , HunterAC, MurrayJC: Long-circulating and target-specific nanoparticles: theory to practice.Pharmacol. Rev.53(2), 283–318 (2001). · DOI
  3. Passirani C BenoitJP: Complement activation by injectable colloidal drug carriers. In: Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press Inc. FL USA 187–230 (2005). · DOI
  4. 10.1016/S0168-3659(99)00248-5 · DOI · Paper page
  5. 10.1007/s11095-007-9284-6 · DOI
  6. 10.1016/j.biomaterials.2009.09.044 · DOI
  7. 10.1016/j.biomaterials.2008.04.036 · DOI
  8. 10.1016/j.phrs.2009.11.013 · DOI
  9. Jones A , HarrisAL: New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.Cancer J. Sci. Am.4(4), 209–217 (1998).
  10. 10.1054/bjoc.2001.1809 · DOI
  11. 10.1016/S0169-409X(98)00003-9 · DOI
  12. 10.1023/A:1025785505977 · DOI
  13. 10.1073/pnas.95.8.4607 · DOI · Paper page
  14. Maeda H , MatsumuraY: Tumoritropic and lymphotropic principles of macromolecular drugs.Crit. Rev. Ther. Drug Carrier Syst.6(3), 193–210 (1989).
  15. 10.1016/j.nano.2005.06.004 · DOI
  16. 10.1016/j.ejpb.2004.02.016 · DOI
  17. 10.1016/j.biomaterials.2005.04.041 · DOI
  18. 10.1177/153303460500400605 · DOI
  19. 10.1016/j.phrs.2010.03.005 · DOI
  20. 10.1016/0014-5793(87)80506-9 · DOI
  21. 10.1038/288602a0 · DOI
  22. 10.1073/pnas.77.7.4089 · DOI
  23. 10.1016/S0140-6736(00)02074-2 · DOI
  24. 10.1016/S0959-8049(01)00171-X · DOI
  25. 10.1023/A:1010618632738 · DOI
  26. 10.1016/S0378-5173(01)00986-3 · DOI
  27. 10.1016/S1359-6349(10)70002-1 · DOI
  28. 10.1016/j.addr.2007.08.044 · DOI · Paper page
  29. 10.1016/S0168-3659(01)00275-9 · DOI · Paper page
  30. 10.1158/1078-0432.CCR-03-0655 · DOI · Paper page
  31. 10.3109/07357900903179591 · DOI
  32. Park SR , OhDY, KimDWet al.: A multi-center, late Phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.Oncol. Rep.12(5), 1059–1064 (2004).
  33. 10.4143/crt.2009.41.1.1 · DOI
  34. 10.1161/01.CIR.0000133187.74800.B9 · DOI
  35. 10.1016/j.ygyno.2004.09.046 · DOI
  36. 10.1016/S1040-8428(00)00107-4 · DOI
  37. 10.2165/00003088-200342050-00002 · DOI
  38. 10.3816/CLM.2008.n.001 · DOI
  39. 10.1081/CNV-100103136 · DOI
  40. 10.1016/j.ctrv.2008.01.008 · DOI
  41. Venne A , LiS, MandevilleR, KabanovA, AlakhovV: Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells.Cancer Res.56(16), 3626–3629 (1996).
  42. 10.1016/S0927-7765(99)00064-8 · DOI
  43. 10.1038/sj.bjc.6601856 · DOI · Paper page
  44. Duska LR , PensonR, SupkoJGet al.: A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.Clin. Cancer Res.5(6), 1299–1305 (1999).
  45. Valle JW , ArmstrongA, NewmanCet al.: A Phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.Invest. New Drugs1–9 (2010).
  46. 10.1053/clon.2000.9147 · DOI
  47. 10.1007/s11864-006-0009-6 · DOI
  48. 10.1007/BF00686277 · DOI
  49. 10.1007/s002800050855 · DOI
  50. 10.1054/bjoc.2001.1723 · DOI
  51. 10.1016/S0169-5002(01)00278-1 · DOI
  52. 10.1023/A:1011199028318 · DOI
  53. 10.1007/s002800100371 · DOI
  54. 10.1023/A:1016201732368 · DOI
  55. 10.3816/CLC.2000.n.025 · DOI
  56. 10.1038/sj.bjc.6603345 · DOI
  57. 10.1007/BF02975379 · DOI
  58. Yu NY , ConwayC, PenaRLS, ChenJY: STEALTH® liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.Anticancer Res.27(4B), 2541–2545 (2007).
  59. 10.1158/1078-0432.CCR-07-1035 · DOI
  60. 10.1038/clpt.2009.141 · DOI
  61. 10.1126/science.1095833 · DOI · Paper page
  62. 10.1016/j.ejpb.2008.11.010 · DOI
  63. 10.1038/nnano.2007.387 · DOI · Paper page
  64. 10.1073/pnas.95.8.4607 · DOI · Paper page
  65. Yuan F , DellianM, FukumuraDet al.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.Cancer Res.55(17), 3752–3756 (1995).
  66. 10.1080/10611860701539584 · DOI
  67. 10.1007/978-3-540-78281-0_13 · DOI
  68. 10.1007/s10856-008-3581-4 · DOI
  69. 10.1016/S0024-3205(97)01175-2 · DOI
  70. Wang ZY , SternIJ: Disposition in rats of a polyoxypropylene–polyoxyethylene copolymer used in plasma fractionation.Drug Metab. Dispos.3(6), 536–542 (1975). · DOI
  71. 10.1023/A:1018998203127 · DOI
  72. 10.1016/S1359-6446(02)02444-3 · DOI
  73. 10.1016/j.bbamem.2009.06.022 · DOI
  74. 10.1016/j.biomaterials.2008.12.070 · DOI
  75. 10.1016/j.colsurfb.2009.04.017 · DOI
  76. 10.1016/S0168-3659(02)00462-5 · DOI
  77. 10.1016/j.ijpharm.2007.11.005 · DOI
  78. 10.1016/j.jconrel.2006.08.001 · DOI
  79. 10.1016/j.jconrel.2007.02.010 · DOI · Paper page
  80. 10.1124/jpet.104.078113 · DOI
  81. Laverman P , CarstensMG, BoermanOCet al.: Factors affecting the accelerated blood clearance of polyethylene glycol–liposomes upon repeated injection.J. Pharmacol. Exp. Ther.298(2), 607–612 (2001). · DOI
  82. 10.1007/s11095-009-9943-x · DOI
  83. 10.1016/j.jconrel.2006.11.015 · DOI
  84. 10.1016/j.ijpharm.2008.06.004 · DOI
  85. 10.1021/bc0497719 · DOI
  86. 10.1016/j.ymthe.2005.09.014 · DOI
  87. 10.1016/j.biomaterials.2010.02.049 · DOI
  88. 10.1080/10611860290031868 · DOI
  89. 10.1038/nrc1958 · DOI
  90. Hong RL , HuangCJ, TsengYLet al.: Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?Clin. Cancer Res.5(11), 3645–3652 (1999).
  91. 10.1016/S0168-3659(03)00271-2 · DOI
  92. 10.1016/j.ijpharm.2007.02.011 · DOI
  93. 10.1016/j.addr.2008.08.005 · DOI
  94. 10.1023/A:1020138622686 · DOI
  95. 10.1016/S1359-6446(03)02988-X · DOI
  96. 10.1038/nrc903 · DOI
  97. 10.1038/sj.onc.1204000 · DOI
  98. 10.1016/j.jconrel.2007.03.012 · DOI
  99. 10.1016/j.ejps.2007.05.113 · DOI
  100. 10.1007/s00262-006-0273-0 · DOI
  101. 10.1016/j.addr.2006.01.026 · DOI
  102. Kou G , GaoJ, WangHet al.: Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5–1 single-chain antibody.J. Biochem. Mol. Biol.40(5), 731–739 (2007).
  103. 10.1158/0008-5472.CAN-05-4199 · DOI
  104. Park JW , HongK, KirpotinDBet al.: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.Clin. Cancer Res.8(4), 1172–1181 (2002).
  105. 10.1016/0005-2736(95)00138-S · DOI
  106. 10.1021/bc050113d · DOI
  107. 10.1073/pnas.152463399 · DOI
  108. 10.1016/S0142-9612(03)00348-X · DOI
  109. 10.1016/j.biomaterials.2007.06.011 · DOI
  110. 10.1007/BF01740936 · DOI
  111. 10.1155/2009/439389 · DOI
  112. 10.1146/annurev.med.56.062904.144915 · DOI
  113. 10.1016/j.cbpa.2005.06.011 · DOI
  114. 10.1158/0008-5472.CAN-04-2550 · DOI
  115. 10.1073/pnas.0601755103 · DOI
  116. 10.1016/j.drup.2005.10.002 · DOI
  117. 10.1016/S0168-3659(03)00240-2 · DOI
  118. 10.1016/j.ccr.2009.10.013 · DOI
  119. 10.1016/j.urolonc.2007.03.017 · DOI
  120. 10.1016/S0168-3659(97)00236-8 · DOI
  121. 10.1016/S1461-5347(00)00255-8 · DOI
  122. 10.1016/j.ijpharm.2009.05.065 · DOI
  123. 10.1016/j.tibtech.2008.06.007 · DOI
  124. 10.1016/j.bmc.2009.02.043 · DOI
  125. 10.1083/jcb.200910104 · DOI
  126. 10.1016/S0014-5793(97)00905-8 · DOI
  127. 10.1038/nmat1879 · DOI
  128. 10.1016/j.ejpb.2007.06.010 · DOI
  129. 10.1016/j.polymer.2007.09.048 · DOI
  130. 10.1016/j.jcis.2008.09.080 · DOI
  131. 10.1021/mp900090z · DOI
  132. 10.1016/0142-9612(95)00322-3 · DOI
  133. 10.1016/j.bbamem.2006.12.013 · DOI
  134. 10.1016/j.ijpharm.2007.02.011 · DOI
  135. 10.1016/S0378-5173(96)04674-1 · DOI
  136. 10.1016/0378-5173(95)04074-9 · DOI
  137. 10.1023/B:PHAM.0000045229.87844.21 · DOI
  138. 10.1007/s11095-006-9662-5 · DOI
  139. 10.1016/S0168-3659(99)00166-2 · DOI
  140. 10.1016/S0378-5173(98)00282-8 · DOI
  141. 10.1006/phrs.2000.0695 · DOI
  142. 10.1211/0022357001774976 · DOI
  143. 10.1007/s11095-006-9061-y · DOI
  144. 10.1016/S0927-7765(99)00156-3 · DOI
  145. 10.1002/jps.2600840420 · DOI
  146. 10.1016/0168-3659(95)00053-B · DOI
  147. 10.1039/b902714a · DOI
  148. 10.1016/j.biomaterials.2007.05.026 · DOI
  149. 10.1016/S0168-3659(01)00451-5 · DOI
  150. 10.1016/j.ejpb.2008.09.011 · DOI
  151. 10.1016/j.nano.2009.02.002 · DOI
  152. 10.1016/S0378-5173(03)00224-2 · DOI
  153. 10.1016/S0168-3659(01)00218-8 · DOI · Paper page
  154. 10.1016/j.jconrel.2008.09.086 · DOI
  155. 10.1080/10611860802088598 · DOI
  156. 10.1016/j.ejpb.2006.12.017 · DOI
  157. 10.1016/S0168-3659(99)00063-2 · DOI
  158. 10.1111/j.1745-7254.2005.00216.x · DOI
  159. 10.1124/jpet.102.039669 · DOI
  160. 10.1007/s00018-007-6390-x · DOI
  161. 10.1021/bm060711a · DOI · Paper page
  162. 10.1016/j.jconrel.2004.01.010 · DOI
  163. 10.1016/j.jconrel.2007.02.013 · DOI
  164. 10.1021/jp905781g · DOI
  165. 10.1016/S0378-5173(98)00280-4 · DOI
  166. 10.1016/S0168-3659(00)00367-9 · DOI
  167. 10.1021/bc0340363 · DOI
  168. 10.1021/bc00030a001 · DOI
  169. 10.1016/0005-2736(94)90025-6 · DOI
  170. 10.1002/jps.2600840904 · DOI
  171. 10.1016/j.colsurfb.2010.03.037 · DOI
  172. 10.1016/j.jconrel.2010.01.017 · DOI
  173. 10.1002/(SICI)1097-4636(20000615)50:4<557::AID-JBM11>3.0.CO;2-R · DOI
  174. 10.1023/B:PHAM.0000003376.57954.2a · DOI
  175. 10.1007/s11095-007-9425-y · DOI
  176. 10.1002/jbm.a.31615 · DOI
  177. 10.1002/jps.20397 · DOI
  178. 10.1016/j.jconrel.2005.03.030 · DOI
  179. Gabizon A , HorowitzAT, GorenD, TzemachD, ShmeedaH, ZalipskyS: In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.Clin. Cancer Res.9(17), 6551–6559 (2003).
  180. 10.1016/j.jconrel.2004.02.003 · DOI
  181. 10.1016/j.biomaterials.2005.05.028 · DOI
  182. 10.1016/j.jconrel.2009.08.006 · DOI
  183. 10.2174/156720110791011783 · DOI
  184. Graul AI , ProusJR, BarrionuevoMet al.: The year‘s new drugs and biologics – 2007.Drug News Perspect.21(1), 7–35 (2008).
  185. 10.1038/sj.bjc.6603855 · DOI · Paper page
  186. 10.1016/j.pharmthera.2010.07.007 · DOI
  187. 10.1053/j.seminoncol.2004.08.003 · DOI
  188. 10.1634/theoncologist.10-3-205 · DOI
  189. 10.1111/j.1349-7006.2004.tb02495.x · DOI
  190. 10.1093/annonc/mdh092 · DOI
  191. 10.3109/08982109409037063 · DOI
  192. Seetharamu N , KimE, HochsterH, MartinF, MuggiaF: Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.Anticancer Res.30(2), 541–545 (2010).
  193. 10.1517/13543780903114168 · DOI
  194. Boulikas T : Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts.Oncol. Rep.12(1), 3–12 (2004).
  195. 10.1038/sj.bjc.6602772 · DOI · Paper page
  196. 10.1158/1078-0432.CCR-08-1405 · DOI
  197. 10.1016/j.addr.2010.05.008 · DOI
  198. 10.1111/j.1349-7006.2009.01103.x · DOI

Cited by

Sorted by citations

See all 164

Metadata

Authors
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C.
Venue
Nanomedicine
Publisher
Informa UK Limited
Published
2010-11
Volume
5
Issue
9
Pages
1415-1433
ISSN
  • 1743-5889
  • 1748-6963
DOI
10.2217/nnm.10.113
Cited by
164
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting. https://app.cochat.ai/papers/10.2217/nnm.10.113
The paper
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010). The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting. Nanomedicine. https://doi.org/10.2217/nnm.10.113